Reviews/Ultra Processed Foods/Ultra-processed food raises hypertension risk
Cardiometabolic · UPF-CM-04 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Across four separate groups of people, those who ate more ultra-processed food tended to have slightly higher blood pressure or a greater chance of having high blood pressure. This pattern held in Spanish adults with metabolic syndrome [8], Brazilian [17] and Canadian [21] children, and Brazilian women [19]. But every one of these studies just observed people's existing diets and measured their blood pressure, so none can show that the food caused the rise rather than simply travelling alongside it. The size of the blood-pressure differences was very small, well under one mmHg [21][8]. The only controlled feeding experiments in this evidence set were built around weight or deliberately matched salt and did not test blood pressure at all [1][4][6], and the one study using a hypertension diagnosis simply asked people at a single point in time [19]. So the panel found a consistent but modest association and no experiment proving cause.
Four independent observational datasets point the same way: higher UPF intake tracks with higher blood pressure or hypertension. In adults with metabolic syndrome, the highest versus lowest UPF quartile showed diastolic blood pressure β=0.67 (0.29 to 1.06) [8]; in Canadian children each 10% increase in UPF was associated with 0.31 mmHg higher diastolic BP (95% CI: 0.01, 0.61) [21]; Brazilian 6-year-olds showed UPF associated with systolic (P=.05) and diastolic blood pressure [17]; and women with hypertension had 14% higher odds of greater UPF consumption [19]. No controlled-feeding trial here reports UPF raising blood pressure, and the trials that could have [1][4][6] matched sodium, excluded hypertensives, or did not report BP. The contested point: The division is whether the UPF label marks an independent cause or a proxy for sodium and adiposity: [21] reports the UPF-to-diastolic association was partially mediated (~27%) by child BMI, and [14] shows reformulating sodium out of processed foods lowered systolic BP by -2.1 mmHg (95% CI: -3.6, -0.6). The direction is consistent, but whether 'processing' per se drives the signal is unresolved in this corpus.
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ultra Processed Foods, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No causal evidence: all four included papers are observational associations. The corpus contains no RCT reporting UPF raising blood pressure or hypertension incidence; the controlled-feeding trials [1][4][6] matched sodium, excluded hypertensives, or did not report BP.
Effect sizes are sub-clinical: 0.31 mmHg diastolic per 10% UPF [21] and 0.67 mmHg diastolic [8] are far below any clinically meaningful hypertension threshold.
Where it remains uncertain. Effects are fractions of a mmHg, one pillar is cross-sectional with hypertension by prior diagnosis [19], and ~27% of the children's signal was mediated by BMI [21] while sodium reformulation alone lowered BP [14], so the UPF label may proxy sodium and weight rather than act independently.
Aleatory
The children's estimate has a lower bound essentially at zero (0.31 mmHg; 95% CI: 0.01, 0.61 [21]) and the paediatric systolic association sits at P=.05 [17], so sampling variation leaves the signal fragile.
Epistemic
The controlled-feeding trials were built around weight or energy [1][4][6]; none randomised UPF and measured blood pressure, so the experiment that would settle causation is absent.
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Longitudinal adult evidence (N=5373) linking higher UPF consumption to higher diastolic blood pressure
“when comparing the highest versus the lowest quartile of UPF consumption, positive associations were found for several CMR factors: weight (kg, β = 1.09; 95% confidence interval 0.91 to 1.26); BMI (kg/m2, β = 0.39; 0.33 to 0.46); waist circumference (cm, β = 1.03; 0.81 to 1.26); diastolic blood pressure (mm Hg, β = 0.67; 0.29 to 1.06)”
Panel auditInternal validity: medium · scope of inference: Change in objectively measured cardiometabolic factors including DBP with changing UPF intake in older adults with metabolic syndrome.Key limitations: diastolic only, no hypertension diagnosis · observational exposure · metabolic-syndrome population only
Paediatric evidence (N=305) associating UPF consumption with both systolic and diastolic blood pressure
“systolic blood pressure was associated with UPF consumption at 6 years (P = .05), birth weight (P = .02), waist circumference (P < .01), and physical activity (P = .04), whereas diastolic blood pressure was associated with UPF consumption at 3 and 6 years (P = .01 and P < .01, respectively)”
Panel auditInternal validity: medium · scope of inference: Association of early UPF intake with blood pressure in 6-year-old southern Brazilian children.Key limitations: cross-sectional association · children only · borderline systolic signal
Cross-sectional adult evidence (N=1702) linking hypertension to higher UPF consumption, though direction of causation is unestablished
“Women with SAH had a 14% higher odds of consuming greater amounts of UPF.”
Panel auditInternal validity: low · scope of inference: Association of UPF intake with hypertension among reproductive-age women in Brazilian favelas.Key limitations: cross-sectional, reverse-framed association · no CI or p reported · self-reported diagnosis and single recall
3 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Directionally consistent cross-population associations support the claim but the absence of interventional evidence on the BP endpoint, sub-clinical effect sizes, and confounding by sodium and BMI cap confidence below the Likely band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No controlled-feeding trial on the blood-pressure endpoint. Causation cannot be inferred from the four observational studies [8][17][19][21]; the feeding trials that exist did not measure BP as an outcome under matched conditions [1][4][6]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised crossover feeding trial assigning UPF versus minimally processed diets with blood pressure as a pre-registered primary outcome, not matching sodium between arms.
Open question: Does ultra-processed food raise blood pressure when sodium is held equal between diets? Why it is still open: No feeding trial here measures BP under UPF versus non-UPF arms, and [14] suggests sodium alone moves BP.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19